RedHill Biopharma Ltd.
RedHill Biopharma Ltd is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $4.4M market cap.
Most recent earnings call: Q1 FY22 on Jun 23, 2022.
5 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks RDHL's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RDHL.
$ curl https://api.spokenalpha.com/v1/companies/RDHLFAQ
Spoken Alpha indexes RDHL's earnings call transcripts at https://spokenalpha.com/companies/RDHL. Each call links to attributed speakers and parsed analyst Q&A. RedHill Biopharma Ltd.'s own investor relations page is at https://www.redhillbio.com/investors/overview/default.aspx.
RedHill Biopharma Ltd. (RDHL) held its most recent earnings call on 2022-06-23, covering fiscal Q1 2022.
RedHill Biopharma Ltd. (RDHL) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $0.47 | $0.49 | -4.9% | +6.4% | +8.4% |
| Q4 FY2022 | $0.50 | $0.54 | -6.5% | +3.1% | +3.1% |
| Q3 FY2022 | $0.53 | $0.58 | -8.1% | +9.7% | +12.4% |
| Q2 FY2022 | $0.67 | $0.70 | -4.2% | +6.7% | +8.7% |
| Q1 FY2021 | $0.68 | $0.79 | -14.2% | +9.7% | +7.6% |
| Q4 FY2021 |
| $0.57 |
| $0.67 |
| -15.5% |
| +8.9% |
| +10.9% |
| Q3 FY2021 | $0.72 | $0.81 | -11.4% | +4.6% | +2.0% |
| Q2 FY2021 | $0.62 | $0.65 | -4.1% | -1.1% | -1.0% |
| Q1 FY2020 | $0.72 | $0.83 | -13.3% | -2.1% | +0.4% |
| Q4 FY2020 | $0.59 | $0.65 | -9.7% | +4.0% | +1.5% |